This is the classic website, which will be retired eventually. Please visit the modernized instead.

Key Record Dates Identifier: NCT05445778
Brief Title: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

First Submitted : June 30, 2022
First Submitted that Met QC Criteria : June 30, 2022
First Posted : July 6, 2022

Last Update Submitted that Met QC Criteria : February 6, 2024
Last Update Posted : February 8, 2024